M Santoni
Overview
Explore the profile of M Santoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, et al.
ESMO Open
. 2024 Mar;
9(4):102943.
PMID: 38492275
Background: In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data...
2.
Interno V, Massari F, Ruda R, Maiorano B, Caffo O, Procopio G, et al.
ESMO Open
. 2023 Jul;
8(4):101598.
PMID: 37467658
Background: The treatment of patients with brain-spread renal cell carcinoma (RCC) is an unmet clinical need, although more recent therapeutic strategies have significantly improved RCC patients' life expectancy. Our multicenter,...
3.
Paris V, Cola E, Santoni M, Pioli F, Piermartiri M, Orici F, et al.
Eur J Obstet Gynecol Reprod Biol
. 2023 May;
285:212-213.
PMID: 37127477
No abstract available.
4.
Rebuzzi S, Signori A, Buti S, Banna G, Murianni V, Damassi A, et al.
ESMO Open
. 2022 Dec;
7(6):100634.
PMID: 36493602
Background: The Meet-URO score allowed a more accurate prognostication than the International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated metastatic renal cell carcinoma (mRCC) by adding the pre-treatment...
5.
Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M, et al.
Ann Oncol
. 2020 Mar;
31(4):470-479.
PMID: 32139297
Prostate cancer is the most common cancer and second leading cause of cancer-related death in American men. Antiandrogen therapies are part of the standard of therapeutic regimen for advanced or...
6.
Cannavale A, Lucatelli P, Corona M, Nardis P, Basilico F, De Rubeis G, et al.
Clin Radiol
. 2019 Dec;
75(3):169-178.
PMID: 31810539
In recent years, there has been tremendous progress in endovascular aneurysm repair (EVAR) techniques and devices. This process has seen a change in incidence, risk factors, and treatment of endoleaks...
7.
Rinaldi S, Santoni M, Leoni G, Fiordoliva I, Marcantognini G, Meletani T, et al.
Support Care Cancer
. 2018 Nov;
27(4):1255-1261.
PMID: 30406916
Purpose: Hyponatremia and bone metastasis (BMs) are known as negative prognostic factors in patients affected by metastatic non-small cell lung cancer (NSCLC). Hyponatremia is associated with higher risk of osteoporosis...
8.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al.
Ann Oncol
. 2015 Dec;
27(2):366.
PMID: 26685011
No abstract available.
9.
Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, et al.
Expert Opin Drug Metab Toxicol
. 2015 Nov;
12(1):57-75.
PMID: 26565919
Introduction: Tumor development results from a cancer-induced immunosuppression (immune-editing). Immunotherapy has revolutionized the treatment paradigm for many malignancies, putting clinicians before novel toxicities, of immune-mediated etiology (immune-related adverse events). Areas...
10.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al.
Ann Oncol
. 2015 Jul;
26(10):2107-13.
PMID: 26216384
Background: First-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC), but it is frequently associated with relevant toxicities and subsequent dose reductions. Alternative schedules, such as 2-week-on treatment and...